Dr. van ‘t Veer is a world-renowned molecular biologist whose research focuses on precision medicine to advance patient management based on knowledge of the genetic makeup of the tumor and the patient. As inventor of MammaPrint she has made seminal impact on “rightsizing” the treatment of breast cancer and on molecular genomics. Dr. van ‘t Veer is Biomarker Committee Chair for the multicenter clinical trial I-SPY 2, overseeing the processes for FDA-IDE biomarker usage and qualifying biomarker companion diagnostics. She has over 330 peer-reviewed scientific articles and is co-inventor of 6 patents. Dr. van t Veer received the 2007 ESMO life-time achievement award and the prestigious European Union Women Innovator Award, 2nd prize in 2014. Dr. van ‘t Veer earned her PhD in Medicine at the University of Leiden as well as two postdoctoral fellowships, at the Cancer Center of Harvard Medical School and Mass General Hospital followed at The Netherlands Cancer Institute.
Track Chair: Cindy Perettie, Roche